TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03976726

Intervention type: DEVICE
Intervention: Comparison of physcial parameters
Description: Increasement of weight, volume expansion and decrease of density are measured.

Intervention type: DEVICE
Intervention: Comparison of physcial parameters
Description: Increasement of weight, volume expansion and decrease of density are measured.

Intervention type: DEVICE
Intervention: Comparison of physcial parameters
Description: Increasement of weight, volume expansion and decrease of density are measured.
Study: NCT04980963

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Support Technology (CST)
Description: Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Support Technology (CST)
Description: Cognitive Support Technology (CST) products and strategies are used to help people with disabilities compensate for or accommodate cognitive limitations (including those related to interpersonal communication and social cognition) that present difficulties for them in the performance of desired social roles, especially education and employment. CSTs may be mainstream everyday technologies such as tablet computers or they may be specialized devices designed for specific goals such as step-by-step instruction in the performance of a particular task (Scherer, 2012).
Study: NCT00694928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clindamycin phosphate/butoconazole nitrate
Description: semi-solid, single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: butoconazole nitrate
Description: semi-solid, single dose
Study: NCT00215657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
Study: NCT03153202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: once daily oral intake ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: once daily oral intake ibrutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV pembrolizumab on Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200mg IV pembrolizumab on Day 1 of each cycle
Study: NCT04457726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Specific T Cells
Description: Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Specific T Cells
Description: Eligible patients will receive a single infusion of SARS-CoV-2 specific T cells intravenously.
Study: NCT00123526

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
Study: NCT03115489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Treatment (Group T)
Description: Patients will receive traditional drug infusions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Infusion (Group K)
Description: Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
Study: NCT02690480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991 (Palbociclib)
Description: Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.~Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs
Study: NCT03177837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT02706093

Intervention type: OTHER
Group type: OTHER
Intervention: High Intensity Interval Training #1
Description: (HIIT#1) 10 x 1 min. at \~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .

Intervention type: OTHER
Group type: OTHER
Intervention: Moderate intensity continuous training
Description: Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.

Intervention type: OTHER
Group type: OTHER
Intervention: High Intensity Interval Training #2
Description: (HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax \[25min; \~150kcals; 4d/wk\]

Intervention type: OTHER
Group type: OTHER
Intervention: High Intensity Interval Training #3
Description: (HIIT #3) 5 x 1 min at 90%HRmax \[15min; \~90kcals; 4d/wk\]
Study: NCT02474940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention #1
Description: Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention #2
Description: Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention #3
Description: Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
Study: NCT03336138

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AMA (Assistance for ambulatory patients)
Description: telephone follow-up modality
Study: NCT03579875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI) (Plan 1)
Description: 300 cGy with thymic shielding on day -6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (Plan 1)
Description: 10 mg/kg IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (Plan 1)
Description: 10 mg/kg IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (Plan 1)
Description: 10 mg/kg IV daily on days -5, -4, -3, and -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY) (Plan 1)
Description: 10 mg/kg IV daily on days -5, -4, -3, and -2
Study: NCT02865434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Planar Image with both Hands in Field of View
Description: Subjects in Groups 1-9 and Groups 10 and 11 will receive planar imaging with both hands in the field of view at 60 and 180 minutes post-injection.
Study: NCT00840320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1278863
Description: 15mg, 25mg, 50mg, 150mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study: NCT02201563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Oral minocycline (100mg twice a day) for 3 months
Study: NCT03640013

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hall Technique PMC
Description: Hall Technique primary fitted crowns to restore carious primary molars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hall Technique PMC
Description: Hall Technique primary fitted crowns to restore carious primary molars
Study: NCT03423264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin taken as follows:~Day 1 (evening): 600 mg Day 2 (morning): 600 mg Day 2 (evening): 600 mg Day 3 (morning): 600 mg Day 3 (evening): 900 mg Day 4 (morning): 900 mg Day 4 (evening): 900 mg Day 5 (morning): 900 mg Day 5 (noon): 900 mg Day 5 (evening): 900 mg
Study: NCT03268135

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs
Study: NCT02478359

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching (Walk On!)
Description: The 12-month Walk On! intervention included a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
Study: NCT01351610

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PTA + Infusion of MSC_Apceth
Description: percutaneous transluminal angioplasty followed by infusion of MSC_Apceth

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTA
Description: percutaneous transluminal angioplasty only
Study: NCT02694679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
Study: NCT02380872

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: gingival recession treated with connective tissue graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin
Description: gingival recession treated with platelet rich fibrin
Study: NCT00017186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study: NCT03361007

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Patients who were disqualified from surgical cortical valve replacement by decision of the Heart Team.
Study: NCT02694679

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
Study: NCT04256837

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous electrical auricular vagus nerve stimulation (VNS)
Description: Electrical auricular stimulation is accomplished using a Roscoe Medical TENS 7000 that delivers a programmable electrical current density, frequency, and pulse width. The TENS 7000 will be connected to ear clip (or hand held) electrodes to transcutaneously stimulate the cymba conchae of the ear to activate the auricular branch of the vagus nerve (diagram above), also known as Arnold's nerve, which provides sensory innervation to the skin surrounding the ear canal. Through a neural reflex arc, activation of this sensory nerve sends a neural signal to the brainstem that then activates the efferent vagus nerve through the nucleus of the solitary tract (NTS). This is a well-described and clinically accepted neuromodulatory pathway, as transcutaneous electrical auricular stimulation has been studied to treat seizures, similarly to how invasive electrical vagus nerve stimulation has been approved by the FDA for the past two decades for the same indication.
Study: NCT03643588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYAJOINT Plus
Description: Single-injection, 60 mg / 3 ml (2%) cross-linked hyaluronan
Study: NCT02694679

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBNH
Description: The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
Study: NCT01356238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRC media
Description: Culture media

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sydney IVF media
Description: Culture media
Study: NCT01528709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Description: Atorvastatin 80 mg daily for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10 mg daily
Description: Atorvastatin 10 mg daily for 1 year
Study: NCT00082290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: massage therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: visit with a volunteer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: period of quiet time

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionaire about pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionaire about pain

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: questionaire about pain
Study: NCT04487028

Intervention type: PROCEDURE
Intervention: Fiberoptic Endoscopic Evaluation of Swallowing
Description: This procedure involves inserting a flexible laryngoscope that contains a light source and video camera on the end through the open passage of the nose towards the back of the throat in order to visualize the swallowing mechanism.